Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Cutaneous Research, 4 Newark Street, London, E1 2AT, UK.
Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham, B15 2TH, UK.
Aesthetic Plast Surg. 2021 Oct;45(5):2096-2115. doi: 10.1007/s00266-021-02233-3. Epub 2021 Apr 5.
Enhanced Recovery After Surgery (ERAS) pathways are known to improve patient outcomes after surgery. In recent years, there have been growing interest in ERAS for reconstructive surgery.
To systematically review and summarise literature on the key components and outcomes of ERAS pathways for autologous flap-based reconstruction.
Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Current Controlled Trials, World Health Organization International Clinical Trials Registry Platform and reference lists of relevant studies.
All primary studies of ERAS pathways for free and pedicled flap-based reconstructions reported in the English language.
The primary outcome measure was length of stay. Secondary outcomes were complication rates including total flap loss, partial flap loss, unplanned reoperation within 30 days, readmission to hospital within 30 days, surgical site infections and medical complications.
Sixteen studies were included. Eleven studies describe ERAS pathways for autologous breast reconstructions and five for autologous head and neck reconstructions. Length of stay was lower in ERAS groups compared to control groups (mean reduction, 1.57 days; 95% CI, - 2.15 to - 0.99). Total flap loss, partial flap loss, unplanned reoperations, readmissions, surgical site infections and medical complication rates were similar between both groups. Compliance rates were poorly reported.
ERAS pathways for flap-based reconstruction reduce length of stay without increasing complication rates. ERAS pathways should be adapted to each institution according to their needs, resources and caseload. There is potential for the development of ERAS pathways for chest wall, perineum and lower limb reconstruction.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
加速康复外科(ERAS)方案已被证实可改善手术后患者的预后。近年来,ERAS 在重建手术中受到越来越多的关注。
系统回顾和总结自体皮瓣重建中 ERAS 方案的关键组成部分和结局的文献。
Cochrane 中心对照试验注册库、MEDLINE、EMBASE、当前对照试验、世界卫生组织国际临床试验注册平台和相关研究的参考文献列表。
所有报告英文的游离皮瓣和带蒂皮瓣重建中 ERAS 方案的原始研究。
主要结局测量指标是住院时间。次要结局指标包括并发症发生率,包括总皮瓣失活、部分皮瓣失活、30 天内计划性再手术、30 天内再入院、手术部位感染和医疗并发症。
纳入了 16 项研究。11 项研究描述了自体乳房重建的 ERAS 方案,5 项研究描述了自体头颈部重建的 ERAS 方案。与对照组相比,ERAS 组的住院时间更短(平均减少 1.57 天;95%CI:-2.15 至-0.99)。两组的总皮瓣失活、部分皮瓣失活、计划性再手术、再入院、手术部位感染和医疗并发症发生率相似。ERAS 方案的依从率报告情况较差。
自体皮瓣重建的 ERAS 方案可缩短住院时间,而不增加并发症发生率。应根据每个机构的需求、资源和病例量来调整 ERAS 方案。胸部、会阴和下肢重建的 ERAS 方案具有发展潜力。
证据等级 III:本刊要求作者为每篇文章指定一个证据等级。有关这些循证医学等级的完整描述,请参考目录或在线作者指南 www.springer.com/00266 。